August 13 2026

Summary of Consolidated Financial Results for 1Q of the Fiscal Year Ended March 31, 2027 (Extracted from Japanese version)

[Japanese GAAP]

Company name:	Kidswell Bio Corporation	Listing: Tokyo Stock Exchange
Stock code:	4584	URL: https://www.kidswellbio.com/en/
Representative:	Shinya Kurebayashi, President & CEO	
Contact:	Nao Osuga, Deputy Division Head, Corporate Strategy Division	
	Tel: +81-3-6222-9547	
Preparation of supplementary materials for financial results:		Yes
Holding of financial result meeting:		No

(All amounts are rounded down to the nearest million yen)

1. Consolidated financial results for the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Results of operations (Cumulative) (Percentages shown for net sales and incomes represent year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of the parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
June 30, 2026	1,269	(26.2)	216	17.3	203	16.0	197	26.0
June 30, 2025	1,720	256.3	184	-	175	-	157	-

(Note) Comprehensive income

For the three months ended June 30, 2026: (191) million yen (2.7%), For the three months ended June 30, 2025: 196 million yen (-%)

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2026	3.99	3.90
June 30, 2025	3.31	3.26

(2) Consolidated financial position

	Total assets	Net assets	Capital adequacy ratio
As of	Millions of yen	Millions of yen	%
June 30, 2026	6,130	1,837	29.4
March 31, 2026	6,088	1,653	26.4

(Reference) Shareholders' equity As of June 30, 2026: 1,800 million yen, As of March 31, 2026: 1,606 million yen

2. Cash Dividends

	Annual dividend				
	First quarter	Second quarter	Third quarter	Year end	Annual
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	-	0.00	-	0.00	0.00
Fiscal year ending March 31, 2027	-				
Fiscal year ending March 31, 2027 (Forecast)		0.00	-	0.00	0.00

Note: Revisions to the forecast of cash dividends most recently announced : None

3. Consolidated financial forecast for the fiscal year ending March 31, 2027 (from April 1, 2026, to March 31, 2027)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of the parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Fiscal year ended Mar. 31, 2027	5,000～6,000	(24.1) ～(9.0)	100 ～600	-	-	-	-	-

(Note) For the fiscal year ending March 31, 2027, the Company will disclose its consolidated earnings forecast only for net sales and operating profit in the form of a range. For details, please refer to the attached document, page 5. "Future Outlook."

*** Notes**

(1) Significant changes in the scope of consolidation during the period：None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements：None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

a. Changes in accounting policies due to revisions to accounting standards and other regulations ：None

b. Changes in accounting policies due to other reasons ：None

c. Changes in accounting estimates ：None

d. Restatement ：None

(4) Number of issued shares (common shares)

a. Number of issued and outstanding shares at the period end (including treasury stock)
As of June 30, 2026: 49,636,019 shares
As of March 31, 2026: 49,623,419 shares

b. Number of treasury shares at the end of period
As of June 30, 2026: 144 shares
As of March 31, 2026: 94 shares

c. Average number of shares outstanding during the period
Three months ended June 30, 2026: 49,627,967 shares
Three months ended June 30, 2025: 47,452,944 shares

*This summary report on Kidswell Bio's financial statements is not subject to audit procedures.

*Cautionary statement with respect to forward-looking statements, and other special items

(Notes to information regarding future)
Forecasts regarding future performance in these materials are based on assumptions judged to be valid and the information available to the Company at the time these materials were made. These materials on future performances are not promises by the Company. Actual performance may differ significantly from these forecasts for several reasons. Please refer to "III. Future Outlook" on page 6 for the details.

(How to obtain supplemental financial information)
Materials for the supplemental financial information are available on the Company's website (https://www.kidswellbio.com/en/).

○Table of Contents of the Attachment

I. Business updates and financial results for the current first quarter in FY 2026

Kidswell Bio Corporation (the “Kidswell”) and its consolidated subsidiaries (collectively, the “Group”) are engaged in two businesses: the biosimilar business, which involves the development and the supply of biosimilar active pharmaceutical ingredients etc., (“Biosimilars”), and the cell therapy (regenerative medicine) business, in which our wholly owned subsidiary, S-Quatre Corporation (“S-Quatre”), aims to commercialize cell-based therapies utilizing SQ-SHED, proprietarily developed by S-Quatre.

Note: SHED stands for Stem cells from Human Exfoliated Deciduous teeth.

For the first quarter of the fiscal year, the Group manufactured and delivered Biosimilars in the biosimilar business in accordance with schedules coordinated with partner pharmaceutical companies and other parties. However, due to changes in the competitive environment and market demand surrounding GBS-007 following the launch of an aflibercept biosimilar and its authorized generic (AG) from January 2026 onward, consolidated net sales decreased to 1,269,509 thousand yen, down 26.2% year on year. For the profit, despite the impact of lower net sales, the depreciation of the yen, and changes in the product mix on cost of sales, the Group continued to benefit from measures implemented in the previous fiscal year, including the optimization of supply prices for certain Biosimilars and initiatives to reduce manufacturing costs. In addition, research and development expenses, which are expected to be recorded more substantially from the second quarter onward, decreased year on year in the first quarter. As a result, operating profit increased 17.3% year on year to 216,506 thousand yen, while ordinary profit rose 16.0% to 203,670 thousand yen, representing year-on-year increases in both profit measures. The Group’s performance for the first quarter is progressing in line with the full-year consolidated financial forecast range for the fiscal year under review.

The progress of each business segment during the first quarter is as follows.

1) Biosimilar Business

- Joint Development of New Biosimilars

  In May 2025, Kidswell and Chiome Bioscience Inc. (“Chiome”) entered into a Master Service Agreement for the joint development of new biosimilars and have begun cell line development with Mycenax Biotech Inc. (“Mycenax”) for multiple biosimilar candidates. Additionally, in October 2025, Alfresa Holdings Corporation (“Alfresa”), Kidswell, and Chiome executed a basic agreement for future joint development of new biosimilars, as well as a basic contract to advance joint development for products already undergoing cell line development. Early-stage development of multiple new biosimilars, including cell line development, is progressing steadily.

- Subsidy Program for the Development of Domestic Manufacturing Facilities for Biosimilars

  With the aim of establishing a domestic supply system to ensure a stable supply of biosimilars in Japan, Kidswell is working to build Japan’s first integrated supply chain covering development, manufacturing, and distribution. In May 2025, the project was selected under the Ministry of Health, Labour and Welfare’s (MHLW) subsidy program for manufacturing facility development (“Subsidy Program for the Development of Domestic Manufacturing Facilities for Biosimilars”, the “Program”). Under the Program, Alfresa, Kidswell, and Chiome, together with Mycenax, an important strategic partner in the project, are jointly proceeding with the establishment of manufacturing facilities for biosimilar active pharmaceutical ingredients and drug products in Japan.

  Furthermore, in October 2025, as part of efforts to establish the business infrastructure under the Program, a basic agreement was reached to establish a joint venture that would operate as a contract development and manufacturing organization (CDMO) for biopharmaceuticals, including biosimilars. In November, the four companies entered into an agreement to establish the joint venture, Alfenax Biologics.

2) Cell Therapy Business

- Clinical Research on the Treatment of Cerebral Palsy

  With respect to cerebral palsy, based on the results of joint research conducted with Nagoya University, a clinical research using autologous SQ-SHED (stem cells derived from the patient’s own deciduous teeth) has been underway since June 2023 toward the development of a cell therapy product for cerebral palsy. The research is led by Nagoya University, with S-Quatre participating as a research collaborator. In June 2025, administration of autologous SQ-SHED to the third and final pediatric patient was completed.

  With respect to the safety of autologous SQ-SHED administration in this clinical study, the Data Safety Monitoring Board (DSMB)—an independent body distinct from the research institution, concluded in October 2025 that there were no safety concerns through four weeks after administration. In August 2026, following a review of all three cases through 52 weeks after administration, the DSMB concluded that there were no safety concerns through the 52-week post-administration period.

In November 2025, a preprint presenting the interim analysis results for all three patients through 12 weeks after administration was released, reporting improvements in motor function following treatment. Final 52-week assessments of safety and efficacy have already been completed for the first and second pediatric patients. The 52-week observation period has also been completed for the third patient, and the final assessment is currently underway. The final analysis results of this clinical research are expected to be announced by Nagoya University by the end of 2026.
Furthermore, in January 2026, a joint research paper with Nagoya University was published in a leading international academic journal. The study provided fundamental findings supporting the clinical study, including evidence of the efficacy of SQ-SHED in an animal model of cerebral palsy and partial elucidation of its mechanism of action.

- Progress Toward Clinical Trial Application for the Treatment of Cerebral Palsy
Regarding allogeneic SQ-SHED for the treatment of cerebral palsy (development code: GCT-103), preparations for initiating clinical trials in Japan are currently underway following the joint business development agreement executed with Mochida Pharmaceutical Co., Ltd. (“Mochida”) in March 2025. Under this agreement, Mochida will primarily be responsible for clinical development, while S-Quatre will focus on manufacturing and related activities. At present, following pilot manufacturing of the investigational product, preparations are steadily progressing toward the commencement of clinical trials in Japan, including preparations for commercial-scale manufacturing in compliance with Good Manufacturing Practice (GMP), the international standard for ensuring the quality and safety of pharmaceutical products.

- Development of the SQ-SHED Manufacturing Technology
Toward the future commercial production, S-Quatre has developed a proprietary manufacturing technology optimized for the characteristics of SQ-SHED, in collaboration with Corning Life Sciences (U.S.), a global leader in cell culture equipment. This technology aims to enable large-area cell culture in a low-stress and uniform environment through a multilayer structure that circulates culture medium, thereby allowing mass production and cost reduction while maintaining equivalence to cells cultured using conventional multilayer flasks. Furthermore, development is progressing steadily under a joint development agreement with Nipro Corporation, a CDMO provider, to establish a manufacturing process for late-stage clinical trials and commercial production.

- Progress in Overseas Clinical Development for Cerebral Palsy
The Group announced in February 2026 that it had reached a basic agreement with Treehill Partners, LLC (“Treehill”), a global provider of strategic and financial advisory services specializing in the healthcare sector, to jointly establish a new company in the United States for the primary purpose of accelerating the clinical development of allogeneic SQ-SHED mainly in the U.S. Through this new company, the Group and Treehill will leverage their respective strengths to advance the clinical development of SQ-SHED in the United States. Preparations for overseas clinical trials had already been progressing, and in October 2025, S-Quatre conducted a Pre-IND Meeting with the U.S. Food and Drug Administration (FDA). As a result, agreement and advice were obtained from the FDA regarding the clinical trial plan for company-sponsored trials of allogeneic SQ-SHED targeting cerebral palsy, and preparations toward the future submission of an investigational new drug application (IND) are being advanced based on such agreement and advice.

- Clinical Research on Isolated Hypoganglionosis
With respect to research and development for isolated hypoganglionosis, S-Quatre jointly applied with Kyushu University for the “FY2026 Comprehensive Research Program for Pediatric and Developmental Disorders” administered by the Japan Agency for Medical Research and Development (AMED), and the project was selected in March 2026. This research project will evaluate the safety and efficacy of autologous (patient-derived) SQ-SHED in patients with isolated hypoganglionosis. In this project, S-Quatre will be responsible for the manufacturing and quality control of SHED and will also provide expertise accumulated through its experience in cell manufacturing and clinical development.

- Future Research and Development Strategy
In March 2026, the Company decided to reorganize its R&D structure for the cell therapy business, redefining cerebral palsy as the highest-priority indication and concentrating management resources on this indication. As part of this reorganization, the Tokyo Laboratory was integrated into the Sapporo Research Institute at the end of June 2026, consolidating and streamlining R&D functions. The technical expertise and research findings accumulated at the Tokyo Laboratory, including those related to next-generation SHED, will continue to be leveraged in future R&D activities and business development.
Furthermore, in conjunction with this reorganization of the R&D structure, the Group implemented organizational changes and personnel reassignments effective today, with the objectives of strengthening the alignment between management strategy and R&D strategy, as well as establishing an integrated operational framework for research and development functions in preparation for future clinical development phases. Through these measures, the Group will further optimize the clinical development structure for therapeutics targeting cerebral palsy, the highest-priority indication in its cell therapy

business.

II. Future Outlook

1. Management Policies

The Group pursues its business activities under the corporate philosophy of “Biotech Engineering Company, Striving for Value Creation – For Comprehensive Healthcare System for Children as well as Families and Society –,” and upholds the management vision of “Empowering children and enabling children to empower others.” Leveraging expertise and know-how in biopharmaceutical research and development accumulated through past business activities, the Group promotes R&D initiatives in two business areas.

In the biosimilars business, the objective is to create an environment in which more patients can receive continuous and reliable treatment. To date, Kidswell has contributed to the launch of four biosimilar products and currently generate revenue through the supply of Biosimilars to our partner pharmaceutical companies, as well as royalty income based on the sales performance of those products by our partners. Going forward, in addition to strengthening the stable supply structure and enhancing profitability of existing products, Kidswell intends to actively pursue the development of new biosimilars to support further revenue growth. In promoting this business, Kidswell maintains a management policy that emphasizes balancing development investments and earnings, with the goal of achieving sustainable profitability.

In the cell therapy business (regenerative medicine), the focus is on developing innovative therapies that support patients, particularly those suffering from pediatric or rare diseases, their families, and the healthcare professionals involved in their care. In particular, S-Quatre is focusing on R&D for a cell therapy product for cerebral palsy, its highest-priority indication, as well as clinical development in Japan and overseas and the development of the SQ-SHED manufacturing process. The business is currently at a stage where R&D investment precedes commercialization. Under these circumstances, the Group has established medium- to long-term development investment plans for each major development stage, primarily related to cerebral palsy, and monitors the progress and achievement status of these plans as key management indicators.

By reinvesting the stable earnings generated through the biosimilar business, as well as the biopharmaceutical R&D expertise accumulated over many years, into the development of the high-growth-potential cell therapy business, the Group seeks to maximize synergies between the two business domains and achieve both stability and growth. Through structural reforms, operational efficiency improvements, and optimized allocation of human resources, we aim to establish and maintain a stable consolidated operating profit.

2. Outlook for Future Performance

In the biosimilar business, the switching rate from reference biologics to biosimilars covering GBS-001, GBS-011, and competing products in the same category has exceeded 80%, and the market share of partner pharmaceutical companies has still been stable. With respect to GBS-007 and GBS-010, which are key drivers of the Group’s net sales, the Group will continue to work to ensure a stable supply of Biosimilars while closely monitoring changes in the market environment described below.

Based on this outlook, Kidswell continues to adjust manufacturing and supply plans for Biosimilars in collaboration with partner pharmaceutical companies and CDMOs, while working to support and reinforce a stable supply system. Furthermore, to improve profitability, Kidswell is engaging in discussions with partner pharmaceutical companies to appropriately review supply prices, considering changes in external factors such as overseas cost inflation and yen depreciation. In the previous fiscal year, supply price revisions for certain Biosimilars, as well as a transition to lower-cost manufacturing product, have progressed. As a result, the margin improvement benefits from these measures are expected to be realized throughout the current fiscal year.

Furthermore, from a medium- to long-term perspective, the Group will continue to advance its biosimilar business by prioritizing key initiatives including the development or in-licensing of new biosimilars, and the expansion of its revenue base through the commercialization of such products, as well as the establishment of biopharmaceutical drug substance and drug products manufacturing facilities aimed primarily at securing a stable domestic supply framework for biosimilars, as described above.

With respect to GBS-007, an aflibercept biosimilar and an authorized generic (AG) product have been listed on the National Health Insurance drug price list and launched in the market, leading to changes in the competitive environment of the anti-VEGF agent market in the ophthalmology field. While the launch of these competing products affected the sales trends of GBS-007, Kidswell, in collaboration with our partner pharmaceutical companies, continues to monitor market information such as prescription trends and distribution status of these competing products, and reflects the impact on sales forecast of GBS-007.

In the cell therapy business, clinical development targeting cerebral palsy is progressing in Japan, while also preparations for clinical development in overseas are advancing in collaboration with external organizations. Furthermore, in line with the research and development strategy described above, the Group will execute focused and strategic R&D investments aimed at

steadily advancing the clinical development of cell therapeutics for cerebral palsy, which has been designated as its highest-priority indication.

Based on this future outlook, the Group forecasts its consolidated financial results for the current fiscal year as set forth below. With respect to the current fiscal year, in addition to ongoing coordination and discussions regarding the manufacturing and delivery plans for Biosimilars, the Group is assessing and discussing with relevant parties the impact of changes in the competitive environment in the biosimilar business, as described above, as well as clinical development expenses associated with preparations for the initiation of clinical trials in Japan and overseas in the cell therapy business. Accordingly, only net sales and operating profit are disclosed as ranges.

FY2026: Net sales: 5,000,000 - 6,000,000 thousand yen | Operating income: 100,000 - 1,000,000 thousand yen

Furthermore, regarding the R&D investments for FY2026, the Group will continue to review and evaluate investment plans based on the progress of each initiative and through ongoing discussions and coordination with relevant stakeholders and will make investment decisions accordingly.

1) Biosimilar business
For GBS-010, Kidswell will work to respond to market demand that has exceeded initial expectations. For GBS-007, in light of changes in the competitive environment following the launch of an aflibercept biosimilar and its authorized generic (AG), Kidswell will flexibly coordinate and adjust manufacturing and delivery plans with partner pharmaceutical companies and other relevant parties, while maintaining the stable supply framework necessary to meet market needs. In addition, Kidswell plans to continue investing in the enhancement of its manufacturing framework and cost-reduction initiatives in order to address rising overseas costs and the depreciation of the yen and improve profit margins, as well as in the development of new biosimilars to further strengthen its earnings base.

2) Cell therapy business
The investments are planned for initiating early-stage clinical trials of GCT-103 in Japan and overseas for the corporate-sponsored clinical development of SQ-SHED, as well as additional investments in large-scale manufacturing process development in preparation for late-stage clinical trials and stable commercial supply following product launch. Also, the clinical research targeting isolated hypoganglionosis, which has been selected under AMED research program, will continue to be promoted. Furthermore, as described in the research and development strategy outlined above, the Group will continue to execute R&D investments to steadily advance the clinical development of cell therapeutics targeting cerebral palsy, which has been designated as its highest-priority indication.

As the Group outsources all manufacturing of biosimilars to overseas CDMOs and conducts part of its R&D activities in both the biosimilar business and the cell therapy business in collaboration with overseas companies, fluctuations in prices in overseas markets or in foreign exchange rates may result in increases or decreases in cost of sales and R&D expenses, thereby potentially affecting business performance. Should such circumstances arise, the Group will promptly make disclosures after due examination.

3. Initiatives to Enhance Corporate Value

1) Optimization of Financing and Strengthening of the Financial Base
The Group continues to work toward optimizing financing and strengthening its financial base to maximize corporate value and achieve an early recovery and growth of the share price. In the biosimilar business, while responding to changes in market demand and overseas manufacturing costs, the Group is working to secure a stable earnings base and cash flow through measures including the optimization of supply prices for certain Biosimilars in coordination with partner pharmaceutical companies and other relevant parties.
The Group also continues to strengthen its financial position and diversify its funding sources through the appropriate use of financing from the equity markets and financial institutions. In addition, the full conversion of the 4th Series Unsecured Convertible Bonds with Stock Acquisition Rights was completed in July 2026. Going forward, as the remaining stock acquisition rights are exercised, the Group expects the supply-demand balance for its shares in the equity market to improve further, thereby creating a more favorable environment in which the Group's business performance can be appropriately reflected in its share price.
Going forward, the Group will continue to secure the funds necessary for R&D investment and strengthen its financial base by combining earnings generated from the biosimilar business with various funding sources, including capital and business alliances with development partners, grants and subsidies, and borrowings from financial institutions. In both businesses, the Group will also flexibly review R&D priorities in line with the progress of development activities and their commercial potential, while adjusting the allocation of roles and cost sharing through early-stage partnering and other initiatives.
Through these efforts, the Group will pursue disciplined R&D investment and reduce risk, with the aim of establishing a

balanced financial foundation that achieves both stability and growth without compromising future growth potential.

2) Strengthening Information Disclosure and Enhancing Visibility of Business Value

With the aim of enhancing the visibility of business value, initiatives are being undertaken to improve the quality of information disclosure through strengthened IR and PR activities. In particular, the Group will further expand opportunities for dialogue with institutional investors, analysts, and the media in Japan and overseas, while actively implementing initiatives to raise awareness of the Group and its businesses. Efforts will also continue to enhance disclosure and expand opportunities for investor communication to foster a deeper understanding of the business value of the biosimilar and cell therapy (regenerative medicine) businesses, as well as the progress of R&D activities. Through these initiatives, greater trust with the capital markets and a deeper understanding of the Group will continue to be fostered.

4. Material Events or Conditions Related to the Going Concern Assumption

The Group is making R&D investments aimed at maximizing the business value of its biosimilar business and cell therapy (regenerative medicine) business, while taking into account the balance between earnings generated by the biosimilar business and the working capital requirements associated with the expansion of manufacturing operations in that business. Under this policy, the Group recorded quarterly net income for the first quarter of the current fiscal year.

On the other hand, except for the fiscal year ended March 31, 2025, the Group had continued to record net losses and negative operating cash flows in the fiscal year ended March 31, 2026 and in each fiscal year up to and including the fiscal year ended March 31, 2024. In addition, the Group intends to continue making active R&D investments aimed at maximizing the business value of both businesses. As funding requirements may increase depending on the scale of such investments and the progress of development activities, events or conditions exist that may cast significant doubt on the Group's ability to continue as a going concern.

Nevertheless, to meet the working capital requirements associated with the expansion of the biosimilar business and the funding needs for research activities in both businesses, the Group plans to utilize cash flows generated by the biosimilar business and, as necessary, obtain borrowings from financial institutions and other sources to secure the funds required to continue its operations. Accordingly, the Group believes that there is no material uncertainty related to the going concern assumption.

III. Financial statements and notes to financial statements

(A) Consolidated balance sheet

(Thousands of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	3,294,916	3,233,532
Accounts receivable - trade	731,132	685,942
Work in process	363,560	414,442
Advance payments to suppliers	1,114,493	1,342,360
Other	336,231	218,370
Total current assets	5,840,335	5,894,648
Non-current assets		
Property, plant and equipment	17,619	17,618
Intangible assets	647	618
Investments and other assets	229,794	217,878
Total non-current assets	248,061	236,115
Total assets	6,088,396	6,130,763
Liabilities		
Current liabilities		
Accounts payable - trade	-	385,818
Current portion of long-term borrowings	362,500	425,000
Accounts payable - other	509,315	155,043
Income taxes payable	3,783	43,508
Contract liabilities	1,113,831	1,111,000
Other	160,277	41,043
Total current liabilities	2,149,707	2,161,413
Non-current liabilities		
Convertible-bond-type bonds with share acquisition rights	125,000	125,000
Long-term borrowings	2,062,500	1,925,000
Retirement benefit liability	57,744	43,548
Deferred tax liabilities	39,527	38,354
Total non-current liabilities	2,284,771	2,131,902
Total liabilities	4,434,479	4,293,316
Net assets		
Shareholders' equity		
Share capital	191,516	192,984
Capital surplus	2,566,539	2,568,007
Retained earnings	(1,241,227)	(1,043,324)
Treasury shares	(73)	(82)
Total shareholders' equity	1,516,753	1,717,584
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	89,648	83,406
Total accumulated other comprehensive income	89,648	83,406
Share acquisition rights	47,514	36,455
Total net assets	1,653,916	1,837,447
Total liabilities and net assets	6,088,396	6,130,763

(B) Consolidated statement of income and comprehensive income

(Thousands of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Net sales	1,720,632	1,269,509
Cost of sales	1,123,406	838,120
Gross profit	597,226	431,389
Selling, general and administrative expenses		
Research and development expenses	212,084	32,659
Other	200,489	182,223
Total selling, general and administrative expenses	412,573	214,883
Operating profit	184,652	216,506
Non-operating income		
Gain on sales of materials	300	400
Foreign exchange gains	403	7,071
Miscellaneous income	119	2,875
Total non-operating income	823	10,347
Non-operating expenses		
Interest expenses	8,936	22,864
Interest expenses on bonds	616	194
Miscellaneous losses	306	123
Total non-operating expenses	9,859	23,183
Ordinary profit	175,617	203,670
Extraordinary income		
Gain on sale of non-current assets	-	636
Gain on reversal of share acquisition rights	-	13,294
Gain on Reversal of Loss on Termination of Lease Agreement	-	18,819
Gain on reversal of asset retirement obligations	-	614
Total extraordinary income	-	33,364
Profit before income taxes	175,617	237,034
Income taxes - current	18,490	39,131
Total income taxes	18,490	39,131
Profit	157,126	197,902
Profit attributable to		
Profit attributable to owners of parent	157,126	197,902
Other comprehensive income		
Valuation difference on available-for-sale securities	39,841	(6,241)
Total other comprehensive income	39,841	(6,241)
Comprehensive income	196,968	191,660
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	196,968	191,660